文献速递头颈部肿瘤放疗

HPV阳性口咽癌根治性放化疗后头颈部影像监测策略

Head and neck imaging surveillance strategy for HPV-positive oropharyngeal carcinoma following definitive (chemo)radiotherapy.
PubMed 文献 · Radiother Oncol · 2021-02-16

该研究回顾412例HPV阳性口咽癌根治性放化疗后患者的1036次头颈影像检查,发现影像监测使用模式在临床医生间差异显著,且无临床症状的常规影像监测未显示能识别局部区域失败或毒性。无不良特征的影像「残留」淋巴结常见,连续两次随访影像稳定或退缩者可安全转为临床监测。

要点

  • 影像监测可减少颈清扫需求,但无临床症状的常规影像监测未证明能识别局部区域失败或毒性。
  • 无不良特征的影像「残留」淋巴结常见,连续两次随访影像稳定或退缩者可安全停止影像监测。
  • 影像监测使用模式在临床医生间差异显著。

核心结论

  • 头颈影像监测使用模式在临床医生间差异显著;影像监测减少颈清扫需求,但无临床症状的常规头颈CT/MR监测未证明能识别局部区域失败或毒性。
  • 无不良特征的影像「残留」淋巴结常见;若连续两次随访影像显示稳定或退缩,临床监测而不进一步影像检查在该人群中似安全。

研究设计与样本

  • 回顾性纳入2012至2015年完成根治性放疗或放化疗的全部HPV阳性口咽癌患者,记录治疗后头颈CT/MRI的安排与理由,评估影像发现与肿瘤学结局。

主要发现

  • 共回顾412例患者的1036次扫描:414次为治疗后首次反应评估,622次为后续原因(影像「残留」淋巴结随访293次/175例;局部症状227次/146例;其他17次/16例;未知85次/66例)。
  • 首次治疗后扫描发现192例(47%)患者存在影像「残留」淋巴结。
  • 28例患者接受颈清扫:16例立即(6/16阳性),10例在一次随访扫描后(2/10阳性),2例在第二次随访扫描后(1/2阳性)。
  • 扫描理由为「未说明」的比例在临床医生间差异显著(3-28%,p < 0.001),且均未产生任何阳性影像发现。

关键数值与推荐

  • 影像「残留」淋巴结随访扫描293次/175例;局部症状扫描227次/146例。
  • 颈清扫阳性率:立即组6/16,一次随访扫描后2/10,第二次随访扫描后1/2。
  • 连续两次随访影像稳定或退缩的影像「残留」淋巴结,可临床监测而不进一步影像检查。

临床怎么用

  • 对无不良特征的影像「残留」淋巴结,可连续两次随访扫描(间隔2-3个月)评估稳定性。
  • 若连续两次随访影像显示稳定或退缩,可转为临床监测而不进一步影像检查。
  • 避免无临床症状/体征的常规头颈CT/MR监测,因其未证明能识别局部区域失败或毒性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To describe the utilization pattern of head and neck (HN) surveillance imaging and explore the optimal strategy for radiologic "residual" lymph node (LN) surveillance following definitive (chemo)radiotherapy (RT/CRT) in human papillomavirus (HPV)+ oropharyngeal carcinoma (OPC). METHODS: All HPV+ OPC patients who completed RT/CRT from 2012 to 2015 were included. Schedule and rationale for post-treatment HN-CT/MRI were recorded. Imaging findings and oncologic outcomes were evaluated. RESULTS: A total of 1036 scans in 412 patients were reviewed: 414 scans for first post-treatment response assessment and 622 scans for the following reasons: follow-up of radiologic "residual" LN(s) (293 scans/175 patients); local symptoms (227/146); other (17/16); unknown (85/66). Rate of scans with "unstated" reason varied significantly among clinicians (3-28%, p < 0.001) and none of them yielded any positive imaging findings. First post-treatment scans identified 192 (47%) patients with radiologic "residual" LNs. Neck dissection (ND) was performed in 28 patients: 16 immediately (6/16 positive), 10 after one follow-up scan (2/10 positive), and 2 after 2nd follow-up scan (1/2 positive). Thirty patients had >2 consecutive follow-up scans at 2-3-month intervals, and none showed subsequent imaging progression or regional failure. CONCLUSIONS: Pattern of HN imaging utilization for surveillance varied significantly among clinicians. Imaging surveillance reduces the need for ND. However, routine HN-CT/MR surveillance without clinical symptoms/signs does not demonstrate proven value in identifying locoregional failure or toxicity. Radiologic "residual" LNs without adverse features are common. If two subsequent follow-up scans demonstrate stable/regressing radiologic "residual" LNs, clinical surveillance without further imaging appears to be safe in this population.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Wong ET, Huang SH, O'Sullivan B, et al. Head and neck imaging surveillance strategy for HPV-positive oropharyngeal carcinoma following definitive (chemo)radiotherapy. Radiother Oncol. 2021. PMID: 33600871. doi:10.1016/j.radonc.2021.02.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。